Study of orBec® With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)
Status:
Terminated
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
Use of an oral topically-active glucocorticoid with limited side effects will control the
gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.